745.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$746.61
Aprire:
$754.55
Volume 24 ore:
438.13K
Relative Volume:
0.55
Capitalizzazione di mercato:
$78.84B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
17.94
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
-1.85%
1M Prestazione:
-7.15%
6M Prestazione:
+33.17%
1 anno Prestazione:
+9.57%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling - simplywall.st
Suvretta Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dodge & Cox - MarketBeat
Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Eli Lilly's Weight Loss Empire in Trouble? - The Motley Fool
Tocqueville Asset Management L.P. Sells 6,884 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Hits Day Low of $744 Amid Price Pressure - Markets Mojo
Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Sq - AD HOC NEWS
Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - AOL.com
The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease. - Bitget
Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - AOL.com
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Positive Obesity Phase 3 Trial Results - Yahoo Finance
Regeneron Science Talent Search: Jericho High senior Ashka Shah recounts experience at finals in D.C. - Newsday
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN) - Seeking Alpha
WINTON GROUP Ltd Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Franklin Resources Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Richard Bernstein Advisors LLC Sells 2,449 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Legal & General Group Plc Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital World Investors Acquires 32,348 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lowered by Capital International Inc. CA - MarketBeat
Capital International Investors Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Private Client Services Inc. - MarketBeat
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - The Manila Times
Regeneron Science Talent Search 2026 Recognizes America’s - GlobeNewswire
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative? - simplywall.st
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More ... - Caledonian Record
Jefferies raises Regeneron stock price target on obesity drug data By Investing.com - Investing.com South Africa
Jefferies raises Regeneron stock price target on obesity drug data - Investing.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
REGN: Dupixent and EYLEA HD fuel growth as pivotal pipeline readouts approach in 2024–2025 - TradingView
Capital International Ltd. CA Sells 5,999 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital International Sarl Has $26.31 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $128.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Korea Investment CORP Purchases 5,181 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026 - Meyka
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial - TechTarget
Regeneron (REGN) Reports Positive Phase 3 Results for Obesity Dr - GuruFocus
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Regeneron stock maintained at Buy by Truist on obesity drug data - Investing.com Canada
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China - BioSpace
Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron-licensed obesity drug shows positive phase 3 results in China (REGN:NASDAQ) - Seeking Alpha
Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):